Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Molecular Magic: Decoding the Unique Mechanism of CELMoDs
Noopur Raje, MD
Data Dive: Clinical Evidence Behind CELMoDs
Sagar Lonial, MD, FACP
Safety First: Navigating CELMoD-Associated Toxicities
Joshua Richter, MD
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Next-Generation Innovations: The Future of CELMoDs in Myeloma
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Insights and Updates: New Data on Next-Generation Retinal Treatments
Durga Borkar, MD, MMCi
Veeral Sheth, MD, MBA, FASRS, FACS
Why CELMoDs Matter in Myeloma
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity
Mastering the Sequence: CELMoDs Across Treatment Lines
Real-World Ready: Practical Tips for Community Oncologists
Chairperson’s Perspective: Optimizing Perioperative Therapy in Early-Stage NSCLC: A Multidisciplinary Approach
Heather Wakelee, MD, FASCO
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Precision Targeting: Matching CELMoDs to the Right Patient With Myeloma
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma
Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
Advancing Myasthenia Gravis (MG) Treatment Through Guideline Updates and Emerging Therapies
October 30, 2025
San Francisco, California
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.